http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012112548-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00772 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0026 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 |
| filingDate | 2010-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012112548-A |
| titleOfInvention | Pulsating drug delivery from the lacrimal opening tube |
| abstract | 1. A device for a pulsating supply of the active substance, comprising: a tube inserted into the cavity of the tube for the lacrimal opening; one or more pulsatile dosage units, typically linearly located within the tube, two or more pulsed dosage units containing a core containing the active substance and an encapsulating layer around the core. 2. The device according to claim 1, in which one or more pulsatile dosage units are water-soluble encapsulated granules. The device according to claim 2, wherein the substantially linear arrangement of the pulsed delivery dosage units limits the effect of tear fluid on the pulsed delivery dosage units to one pulsed dosage unit at a time. The device according to claim 2, further comprising a boundary layer between the first pulsatile dosage unit and the second pulsed dosage unit. The device according to claim 1, further comprising a boundary layer between the drug unit of the pulsating feed and the hole in the tube cavity for the lacrimal opening. The apparatus of claim 5, wherein the boundary layer comprises a biodegradable membrane. The device according to claim 5, in which the boundary layer contains a semi-porous membrane. The device according to claim 5, in which the boundary layer contains a grid. The device according to claim 2, in which the material containing the active substance contains poly (epsilon-caprolactone) and ethylene vinyl acetate. The apparatus of claim 9, wherein the poly (epsilon-caprolactone) and ethylene vinyl acetate are each present in an amount of about 50% by weight. The device according to claim 2, in which |
| priorityDate | 2009-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID422744995 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19917616 |
Total number of triples: 19.